How to decide when to drop a crappy plan

Article

In his email, Mike tackles the ongoing question in all of eye care: should I accept (or drop or keep taking) That Crappy Insurance (TCI)? Anyone in optometric practice knows exactly which ones they are.

I recently received an email from my friend and colleague Mike Rothschild, OD, from Carrolton, GA. Mike is a member of the Optometry Times Editorial Advisory Board, authors our practice management department, and heads up Leadership OD, a doctor-to-doctor consulting service. A little-known fact: Mike and I started out practicing in the same small northwest Georgia town. Eventually we both left-I to teach, he to build a mega-practice from scratch in his wife’s hometown.

More from Dr. Bowling: Are optometrists really happy?

In his email, Mike tackles the ongoing question in all of eye care: should I accept (or drop or keep taking) That Crappy Insurance (TCI)? Anyone in optometric practice knows exactly which ones they are. These plans don’t pay enough for the services we provide and place restrictions on what service our patients may have. So we constantly struggle with the “keep or drop” decision, unsure of what to do and worry about the consequences of our decision.

Mike explained that in its simplest form, the decision to be in or out of a given vision plan depends on two factors (does the vision plan pay well, and is the practice schedule full enough?) and can be decided with a simple four-quadrant grid.

This grid yields a keep/drop decision in its simplest form. Other factors, such as the plan’s penetrance rate in your service area and an associated medical plan are other factors to consider. Still, it is a useful device when evaluating the benefit of a vision plan to your practice. I’ve seen practices that take any and every vision plan on the market, thinking that a warm body in the chair is better than none at all, while on the other hand, I’ve never heard an OD say he regretted dropping (insert your favorite TCI here).

More from Dr. Bowling: Oral antibiotics not effective in MGD?

We are all burdened with vision care plans, yet we must prevent our practices from becoming shackled to those that seem to be racing to absolute bargain-basement reimbursements. As Mike Rothschild warns, “If you find yourself cutting corners so you can take more plans, consider that you might be doing a disservice to the people who are willing to choose you over their plan.” Yes, Virginia, they are out there, and they are the ones we all strive to grace our doors.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.